Document is current
Any future updates will be listed below
-
Authors
Donat-Vargas, Carolina https://orcid.org/0000-0002-4523-4148
Guerrero-Zotano, Ángel
Casas, Ana
Baena-Cañada, José Manuel
Lope, Virginia https://orcid.org/0000-0002-6986-4021
Antolín, Silvia
Garcia-Saénz, José Ángel
Bermejo, Begoña
Muñoz, Montserrat
Ramos, Manuel
de Juan, Ana
Jara Sánchez, Carlos
Sánchez-Rovira, Pedro
Antón, Antonio
Brunet, Joan
Gavilá, Joaquín
Salvador, Javier
Arriola Arellano, Esperanza
Bezares, Susana
Fernández de Larrea-Baz, Nerea
Pérez-Gómez, Beatriz https://orcid.org/0000-0002-4299-8214
Martín, Miguel https://orcid.org/0000-0001-9237-3231
Pollán, Marina https://orcid.org/0000-0002-4328-1565
- License Information
-
More Information
Article History
Received: 9 March 2021
Revised: 10 June 2021
Accepted: 8 July 2021
First Online: 6 September 2021
Ethics approval and consent to participate
: The EpiGEICAM study was approved by the Ethics Committees of all 23 participating hospitals. All procedures were in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All participants signed an informed consent, and patient information was anonymized and de-identified prior to analysis.
: Not applicable.
: Ángel Guerrero-Zotano has received institutional grant from Pfizer; has participated in advisory board activities with Novartis, Palex, Pfizer and Astra Zeneca; has received travel grand from Roche, Pfizer and Novartis. Manuel Ramos has received honoraria from Novartis, Roche and Pfizer. Miguel Martín has received honoraria from Roche/Genentech, Lilly, Pfizer, Novartis and Pierre-Fabre; has participated in consulting or advisory board activities with Roche/Genentech, Novartis, Pfizer, Lilly, Astra Zeneca and Taiho Pharmaceutical; has received speakers’ bureau from Lilly/ImClone, Roche/Genentech and Pierre Fabre; has contracted research fees from Roche, Novartis, and PUMA. All remaining authors have declared no conflicts of interest.
